Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Apnimed

News headline image
Apnimed to Present at the Stifel Healthcare Conference
From Apnimed
Via Business Wire
News headline image
Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)
From Apnimed
Via Business Wire
News headline image
Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum
From Apnimed
Via Business Wire
News headline image
Apnimed Expands Senior Leadership Team by Appointing John Cronin, M.D., Senior Vice President, Clinical Development
From Apnimed
Via Business Wire
News headline image
Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference
From Apnimed
Via Business Wire
News headline image
Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)
From Apnimed
Via Business Wire
News headline image
Apnimed Adds Ruoxi Hu, Ph.D., From Morningside Technology Advisory to Its Board of Directors
From Apnimed
Via Business Wire
News headline image
Apnimed to Present at the Jefferies Healthcare Conference
From Apnimed
Via Business Wire
News headline image
New Data Show Clinically Meaningful Improvements for Investigational Oral Pharmacologic Treatment AD504 in People With Obstructive Sleep Apnea
From Apnimed
Via Business Wire
News headline image
Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders
From Apnimed
Via Business Wire
News headline image
Apnimed to Participate in the 21st Annual Needham Virtual Healthcare Conference
From Apnimed
Via Business Wire
News headline image
Apnimed to Participate in the SVB Leerink Global Healthcare Conference
From Apnimed
Via Business Wire
News headline image
Apnimed to Present at the 40th Annual JP Morgan Healthcare Conference
From Apnimed
Via Business Wire
News headline image
Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)
From Apnimed
Via Business Wire
News headline image
Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study With Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea
From Apnimed
Via Business Wire
News headline image
Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment
From Apnimed
Via Business Wire
News headline image
Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease
From Apnimed
Via Business Wire
News headline image
Apnimed Expands Executive Leadership Team Appointing Rob Rode Chief Commercial Officer
From Apnimed
Via Business Wire
News headline image
Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference
From Apnimed
Via Business Wire
News headline image
David P. White, M.D. Appointed Senior Vice President of Medical Affairs at Apnimed
From Apnimed
Via Business Wire
News headline image
Apnimed to Present at the Ladenburg Thalmann Virtual Healthcare Conference
From Apnimed
Via Business Wire
News headline image
Apnimed to Present at the Jefferies Virtual Healthcare Conference
From Apnimed
Via Business Wire
News headline image
New Data Presented at American Thoracic Society Meeting Reinforces the Potential of an Oral Drug Combination Therapy for the Treatment of Obstructive Sleep Apnea
From Apnimed
Via Business Wire
News headline image
Apnimed to Present at the 20th Annual Needham Virtual Healthcare Conference
From Apnimed
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.